HBV Mutation Detail Information

Virus Mutation HBV Mutation P120T


Basic Characteristics of Mutations
Mutation Site P120T
Mutation Site Sentence Except for the combination of sP120T+sA128V, other double combinations (n=11) were only detected in the NA treatment group, and nine of these combinations in the treatment group were detected in HBV variants without antiviral resistance mutations.
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype -
Viral Reference -
Functional Impact and Mechanisms
Disease Hepatitis B, Chronic    
Immune Y
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information Y
Treatment -
Location China
Literature Information
PMID 28300730
Title The enrichment of HBV immune-escape mutations during nucleoside/nucleotide analogue therapy
Author Shan M,Shen Z,Sun H,Zheng J,Zhang M
Journal Antiviral therapy
Journal Info 2017;22(8):717-720
Abstract BACKGROUND: Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance under NA therapy. This study aims to characterize the variability of HBV polymerase and surface antigen in patients with virological breakthrough under NA therapy. METHODS: From 2012 to 2014, serum samples were collected from 156 patients with chronic hepatitis B infection, who had experienced NA therapy for at least 24 weeks and displayed virological breakthrough, while 165 HBV carriers without NA treatment were also enrolled. HBV DNA was quantified and polymerase reverse transcriptase domain was amplified and sequenced. RESULTS: A total of 97 patients in the NA treatment group had resistance mutations, with rtM204I/V/S being the most common substitution (78 of 97), while no resistance mutations were detected in the treatment-naive group. Various escape mutations were detected, and the detection rate was significantly higher in the NA treatment group (38, 24.4%) than that of treatment-naive group (18, 10.9%; P<0.05). Except for the combination of sP120T+sA128V, other double combinations (n=11) were only detected in the NA treatment group, and nine of these combinations in the treatment group were detected in HBV variants without antiviral resistance mutations. CONCLUSIONS: Antiviral resistance mutations were selected by a long duration of NA therapy. Virological breakthrough was not only attributed to the emergence of resistance mutations, but may also be associated with the enrichment of immune-escape mutations.
Sequence Data KX777257-KX777577
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.